# A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-108 in Patients With Onychomycosis

> **NCT00777868** · PHASE2 · COMPLETED · sponsor: **Dow Pharmaceutical Sciences** · enrollment: 135 (actual)

## Conditions studied

- Onychomycosis

## Interventions

- **DRUG:** Low Strength IDP-108
- **DRUG:** High Strength IDP-108
- **DRUG:** High Strength IDP-108 under occlusion
- **DRUG:** Vehicle

## Key facts

- **NCT ID:** NCT00777868
- **Lead sponsor:** Dow Pharmaceutical Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 135 (ACTUAL)
- **Last updated:** 2012-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00777868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00777868, "A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-108 in Patients With Onychomycosis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00777868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*